29,573 Shares in Vericel Co. (NASDAQ:VCEL) Bought by Scholtz & Company LLC

Scholtz & Company LLC purchased a new position in shares of Vericel Co. (NASDAQ:VCEL - Free Report) in the second quarter, according to its most recent disclosure with the SEC. The firm purchased 29,573 shares of the biotechnology company's stock, valued at approximately $1,357,000. Scholtz & Company LLC owned approximately 0.06% of Vericel at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. MCF Advisors LLC lifted its position in Vericel by 86.1% during the 1st quarter. MCF Advisors LLC now owns 482 shares of the biotechnology company's stock worth $25,000 after acquiring an additional 223 shares during the last quarter. CWM LLC grew its position in Vericel by 319.0% in the 2nd quarter. CWM LLC now owns 662 shares of the biotechnology company's stock worth $30,000 after purchasing an additional 504 shares during the last quarter. Nisa Investment Advisors LLC increased its holdings in shares of Vericel by 9.7% during the 2nd quarter. Nisa Investment Advisors LLC now owns 2,484 shares of the biotechnology company's stock worth $114,000 after purchasing an additional 220 shares during the period. Lazard Asset Management LLC raised its position in shares of Vericel by 178.7% during the first quarter. Lazard Asset Management LLC now owns 2,584 shares of the biotechnology company's stock valued at $134,000 after buying an additional 1,657 shares during the last quarter. Finally, RiverPark Advisors LLC bought a new stake in shares of Vericel in the first quarter valued at about $147,000.

Analysts Set New Price Targets

A number of analysts have recently issued reports on VCEL shares. BTIG Research lowered their price objective on Vericel from $56.00 to $55.00 and set a "buy" rating on the stock in a research report on Monday, July 15th. TD Cowen upped their target price on shares of Vericel from $55.00 to $60.00 and gave the company a "buy" rating in a research note on Tuesday, August 27th. Canaccord Genuity Group assumed coverage on Vericel in a report on Friday, August 9th. They set a "buy" rating and a $57.00 price objective on the stock. Canaccord Genuity Group began coverage on Vericel in a research note on Friday, August 9th. They set a "buy" rating and a $57.00 price objective for the company. Finally, StockNews.com raised shares of Vericel from a "sell" rating to a "hold" rating in a report on Thursday, September 5th. One analyst has rated the stock with a hold rating and nine have given a buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $55.75.

Insider Buying and Selling

In related news, insider Sean C. Flynn sold 6,772 shares of the company's stock in a transaction dated Friday, June 21st. The stock was sold at an average price of $45.02, for a total transaction of $304,875.44. Following the sale, the insider now owns 487 shares in the company, valued at $21,924.74. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, insider Sean C. Flynn sold 6,772 shares of the business's stock in a transaction that occurred on Friday, June 21st. The stock was sold at an average price of $45.02, for a total transaction of $304,875.44. Following the transaction, the insider now directly owns 487 shares of the company's stock, valued at approximately $21,924.74. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Sean C. Flynn sold 1,474 shares of Vericel stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $45.84, for a total transaction of $67,568.16. Following the sale, the insider now directly owns 487 shares of the company's stock, valued at approximately $22,324.08. The disclosure for this sale can be found here. In the last ninety days, insiders sold 46,291 shares of company stock valued at $2,329,169. Company insiders own 5.20% of the company's stock.

Vericel Price Performance

Shares of Vericel stock traded up $1.60 during trading on Friday, hitting $45.87. 329,593 shares of the company were exchanged, compared to its average volume of 438,542. The firm has a market capitalization of $2.25 billion, a P/E ratio of -4,594.41 and a beta of 1.67. The firm's fifty day moving average price is $48.43 and its 200 day moving average price is $47.41. Vericel Co. has a 1-year low of $30.18 and a 1-year high of $54.10.

Vericel (NASDAQ:VCEL - Get Free Report) last announced its quarterly earnings results on Thursday, August 1st. The biotechnology company reported ($0.10) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.10). The company had revenue of $52.70 million for the quarter, compared to analysts' expectations of $52.59 million. Vericel had a net margin of 0.37% and a return on equity of 0.35%. The business's quarterly revenue was up 14.8% compared to the same quarter last year. During the same period last year, the firm posted ($0.11) earnings per share. As a group, equities research analysts anticipate that Vericel Co. will post 0.12 earnings per share for the current year.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.